Get the Daily Brief
Latest Biotech News
AI‑driven biologics keep drawing cash: Galux and QuantX close rounds
Galux closed a ₩42 billion (US$29 million) Series B to scale AI‑driven antibody design capabilities and move programs into discovery and preclinical optimization. The funding will be used to...
Top medical groups launch independent vaccine review as NIH signals reforms
The American Medical Association and the Vaccine Integrity Project announced a joint initiative to independently review vaccine science and provide clinicians and families with evidence summaries,...
Capsida confirms cerebral edema in halted gene‑therapy trial fatality
Capsida Biotherapeutics said an autopsy found cerebral edema as the cause of death in a participant from its suspended SYNRGY trial testing CAP‑002 for STXBP1 deficiency. The company said...
Diagnostics momentum: Personalis wins Medicare coverage; VolitionRx expands to Japan
Personalis secured Medicare coverage for its NeXT Personal MRD assay for surveillance in stages I–III non‑small cell lung cancer, citing TRACERx consortium evidence and Nature Medicine...
Lilly buys Orna: $2.4bn bet on in vivo CAR‑T
Eli Lilly agreed to acquire Orna Therapeutics in a deal valued at up to $2.4 billion, moving the pharma into in‑vivo CAR‑T and circular RNA delivery. The transaction gives Lilly immediate access...
FDA rejects Regenxbio therapy — rare‑disease program stalled
The FDA issued a complete response letter rejecting Regenxbio’s RGX‑121 for Hunter syndrome, citing concerns about surrogate endpoints, historical controls, and the robustness of the evidence...
Nektar’s rezpeg holds up at 1 year — durability claim strengthens
Nektar Therapeutics reported one‑year follow‑up data showing rezpegaldesleukin sustained and in some cases deepened skin‑clearance responses in patients with moderate‑to‑severe atopic dermatitis....
Evommune’s EVO301 challenges Dupixent — phase II moves market
Evommune reported that EVO301, an IL‑18–binding long‑acting fusion protein, met primary endpoints in a Phase 2a atopic dermatitis study, delivering statistically significant EASI improvements...
Takeda taps Iambic’s AI — $1.7bn discovery pact
Takeda signed a multiyear discovery and technology collaboration with Iambic Therapeutics reportedly worth $1.7 billion, aiming to accelerate small‑molecule drug discovery across oncology, GI and...
Startups raise fresh capital: ILiAD $115M; Galux $29M
ILiAD Biotechnologies closed an oversubscribed $115 million Series B to advance its whooping cough vaccine toward pivotal Phase 3 studies. The financing is sized to support late‑stage data accrual...
AI drug engines accelerate: Isomorphic claims advance; Insilico expands
Isomorphic Labs announced what it called a major advance in its AI drug‑design engine after rolling out AlphaFold‑derived models in prior years; the company claims enhanced capability to convert...
Ovrlpy exposes 3D overlaps in spatial transcriptomics
Researchers published ovrlpy, a software tool that identifies vertical (z‑axis) signal overlaps and tissue folds in spatial transcriptomics data, exposing a class of artifacts that can confound...
Smart vascular grafts: magnetoelastic sensors enable real‑time stenosis monitoring
Multiple Nature Biotechnology reports described a hemodynamics‑driven magnetoelastic vascular graft that restores flow while wirelessly and continuously diagnosing stenosis in animal models. The...
Medicare covers Personalis’ NeXT Personal MRD test for lung cancer surveillance
The US Centers for Medicare & Medicaid Services granted coverage for Personalis’ NeXT Personal molecular residual disease (MRD) test for surveillance in stages I–III non‑small cell lung cancer....
Lilly buys Orna: $2.4B bet on in vivo CAR‑T
Eli Lilly agreed to acquire Orna Therapeutics in a transaction valued at up to $2.4 billion to gain an in‑vivo CAR‑T capability built on circular RNA and LNP delivery. Lilly framed the deal as a...
FDA rejects Regenxbio therapy: Hunter syndrome bid turned down
The FDA issued a complete response letter rejecting Regenxbio’s RGX‑121 gene therapy for Hunter syndrome, citing concerns about the development program’s ability to define the patient population...
Novo Nordisk sues Hims – Wegovy compounding clash escalates
Novo Nordisk filed patent litigation against Hims & Hers over a compounded pill version of semaglutide marketed by Hims, accusing the telehealth company of unlawfully mass‑marketing an unapproved...
Medicare covers Personalis MRD test: lung cancer surveillance win
The US Centers for Medicare & Medicaid Services granted coverage for Personalis’ NeXT Personal molecular residual disease (MRD) test for surveillance in stages I–III non‑small cell lung cancer....
Circular Genomics licenses circRNA Alzheimer’s IP from WUSTL, MDC
Circular Genomics secured exclusive commercial rights to intellectual property from Washington University in St. Louis and the Max Delbrück Center covering circular RNA (circRNA) biomarkers for...
Eczema drug race... Evommune and Nektar post encouraging long‑term data
Two late‑stage atopic dermatitis programs reported data that investors and clinicians judged noteworthy. Evommune reported positive phase 2a results for EVO301, an IL‑18 fusion protein, achieving...